PXL065 proves safe, well-tolerated ahead of phase 2 trial for NASH

Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a deuterium-stabilized R-stereoisomer of Actos under investigation for nonalcoholic steatohepatitis, according to a press release.“NASH is a major public health concern and is a growing contributor to the burden of end-stage liver disease. There remains an urgent need to develop effective therapeutics for NASH,” Arun Sanyal, MD, from the Virginia Commonwealth University School of Medicine, said in the release. “[Actos] has been shown in multipleRead More

Share on facebook
Share on twitter
Share on linkedin